GB0229583D0 - A process for preparing duloxetine and intermediates for use therein - Google Patents

A process for preparing duloxetine and intermediates for use therein

Info

Publication number
GB0229583D0
GB0229583D0 GBGB0229583.0A GB0229583A GB0229583D0 GB 0229583 D0 GB0229583 D0 GB 0229583D0 GB 0229583 A GB0229583 A GB 0229583A GB 0229583 D0 GB0229583 D0 GB 0229583D0
Authority
GB
United Kingdom
Prior art keywords
duloxetine
acid addition
addition salt
intermediates
yield
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0229583.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9949985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0229583(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Priority to GBGB0229583.0A priority Critical patent/GB0229583D0/en
Publication of GB0229583D0 publication Critical patent/GB0229583D0/en
Priority to PL377380A priority patent/PL377380A1/pl
Priority to CN2007101531328A priority patent/CN101125848B/zh
Priority to RU2005122662/04A priority patent/RU2351594C2/ru
Priority to AT03767973T priority patent/ATE353081T1/de
Priority to EP06075798A priority patent/EP1690861B1/en
Priority to ES03767973T priority patent/ES2279971T3/es
Priority to NZ569874A priority patent/NZ569874A/en
Priority to BR0316902-2A priority patent/BR0316902A/pt
Priority to CN200380109793A priority patent/CN100579975C/zh
Priority to AU2003292396A priority patent/AU2003292396B2/en
Priority to CA002510750A priority patent/CA2510750A1/en
Priority to EP03767973A priority patent/EP1587801B1/en
Priority to MXPA05006659A priority patent/MXPA05006659A/es
Priority to PCT/GB2003/005357 priority patent/WO2004056795A1/en
Priority to DE60311599T priority patent/DE60311599T2/de
Priority to KR1020057011506A priority patent/KR100926723B1/ko
Priority to HR20050657A priority patent/HRP20050657A2/hr
Priority to JP2004561607A priority patent/JP5259048B2/ja
Priority to NZ540881A priority patent/NZ540881A/en
Priority to PT03767973T priority patent/PT1587801E/pt
Priority to US10/539,415 priority patent/US7645890B2/en
Priority to IL169232A priority patent/IL169232A/en
Priority to TNP2005000167A priority patent/TNSN05167A1/en
Priority to IS7915A priority patent/IS7915A/is
Priority to ZA200505656A priority patent/ZA200505656B/en
Priority to MA28400A priority patent/MA27706A1/fr
Priority to AU2010200142A priority patent/AU2010200142B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
GBGB0229583.0A 2002-12-19 2002-12-19 A process for preparing duloxetine and intermediates for use therein Ceased GB0229583D0 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
GBGB0229583.0A GB0229583D0 (en) 2002-12-19 2002-12-19 A process for preparing duloxetine and intermediates for use therein
PT03767973T PT1587801E (pt) 2002-12-19 2003-12-10 Processo para a preparação de duloxetina e de intermediarios para serem utilizados no referido processo
US10/539,415 US7645890B2 (en) 2002-12-19 2003-12-10 Process for preparing duloxetine and intermediates for use therein
MXPA05006659A MXPA05006659A (es) 2002-12-19 2003-12-10 Un proceso para preparar duloxetina e intermediarios para uso en el mismo.
PCT/GB2003/005357 WO2004056795A1 (en) 2002-12-19 2003-12-10 A process for preparing duloxetine and intermediates for use therein
RU2005122662/04A RU2351594C2 (ru) 2002-12-19 2003-12-10 Способ получения дулоксетина и используемые при этом промежуточные соединения
AT03767973T ATE353081T1 (de) 2002-12-19 2003-12-10 Verfahren zur herstellung von duloxetin und deren verwendeten zwischenprodukten
EP06075798A EP1690861B1 (en) 2002-12-19 2003-12-10 A process for preparing duloxetine and intermediates for use therein
ES03767973T ES2279971T3 (es) 2002-12-19 2003-12-10 Procedimiento para preparar duloxetina e intermedios para su uso en dicho procedimiento.
NZ569874A NZ569874A (en) 2002-12-19 2003-12-10 A process for preparing enantiomerically pure N-methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine and intermediates for use therein
BR0316902-2A BR0316902A (pt) 2002-12-19 2003-12-10 Processos para preparar (+)duloxetina e hidrocloreto de (+)duloxetina, sal de ácido quiral e (+)duloxetina, di-p-toluil tartarato de (+)duloxetina, (+)duloxetina e composição farmacêutica
CN200380109793A CN100579975C (zh) 2002-12-19 2003-12-10 度洛西汀的制备方法及其中所用的中间体
AU2003292396A AU2003292396B2 (en) 2002-12-19 2003-12-10 A process for preparing duloxetine and intermediates for use therein
CA002510750A CA2510750A1 (en) 2002-12-19 2003-12-10 A process for preparing duloxetine and intermediates for use therein
EP03767973A EP1587801B1 (en) 2002-12-19 2003-12-10 A process for preparing duloxetine and intermediates for use therein
PL377380A PL377380A1 (pl) 2002-12-19 2003-12-10 Sposób wytwarzania duloksetyny i związki pośrednie do stosowania w tym sposobie
CN2007101531328A CN101125848B (zh) 2002-12-19 2003-12-10 度洛西汀的制备方法及其中所用的中间体
DE60311599T DE60311599T2 (de) 2002-12-19 2003-12-10 Verfahren zur herstellung von duloxetin und deren verwendeten zwischenprodukten
KR1020057011506A KR100926723B1 (ko) 2002-12-19 2003-12-10 둘록세틴의 제조 방법 및 이에 이용하기 위한 중간체
HR20050657A HRP20050657A2 (en) 2002-12-19 2003-12-10 A process for preparing duloxetine and intermediates for use therein
JP2004561607A JP5259048B2 (ja) 2002-12-19 2003-12-10 デュロキセチン（ｄｕｌｏｘｅｔｉｎｅ）を調製するための方法およびその中で使用するための中間体
NZ540881A NZ540881A (en) 2002-12-19 2003-12-10 A process for preparing enantiomerically pure N-methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine and intermediates for use therein
IL169232A IL169232A (en) 2002-12-19 2005-06-16 Process for preparing duloxetine and intermediates for use therein
TNP2005000167A TNSN05167A1 (en) 2002-12-19 2005-06-17 A process for preparing duloxetine and intermediates for use therein
IS7915A IS7915A (is) 2002-12-19 2005-06-24 Ferli til að framleiða dúlóxetín og milliefni tilnotkunar í ferlinu
ZA200505656A ZA200505656B (en) 2002-12-19 2005-07-14 A process for preparing duloxetine and intermediates for use therein
MA28400A MA27706A1 (fr) 2002-12-19 2005-07-18 Procede de preparation de la duloxetine et intermediaires destines a etre utilises dans ledit procede
AU2010200142A AU2010200142B2 (en) 2002-12-19 2010-01-14 A process for preparing duloxetine and intermediates for use therein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0229583.0A GB0229583D0 (en) 2002-12-19 2002-12-19 A process for preparing duloxetine and intermediates for use therein

Publications (1)

Publication Number Publication Date
GB0229583D0 true GB0229583D0 (en) 2003-01-22

Family

ID=9949985

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0229583.0A Ceased GB0229583D0 (en) 2002-12-19 2002-12-19 A process for preparing duloxetine and intermediates for use therein

Country Status (24)

Country Link
US (1) US7645890B2 (https=)
EP (2) EP1587801B1 (https=)
JP (1) JP5259048B2 (https=)
KR (1) KR100926723B1 (https=)
CN (2) CN101125848B (https=)
AT (1) ATE353081T1 (https=)
AU (2) AU2003292396B2 (https=)
BR (1) BR0316902A (https=)
CA (1) CA2510750A1 (https=)
DE (1) DE60311599T2 (https=)
ES (1) ES2279971T3 (https=)
GB (1) GB0229583D0 (https=)
HR (1) HRP20050657A2 (https=)
IL (1) IL169232A (https=)
IS (1) IS7915A (https=)
MA (1) MA27706A1 (https=)
MX (1) MXPA05006659A (https=)
NZ (2) NZ569874A (https=)
PL (1) PL377380A1 (https=)
PT (1) PT1587801E (https=)
RU (1) RU2351594C2 (https=)
TN (1) TNSN05167A1 (https=)
WO (1) WO2004056795A1 (https=)
ZA (1) ZA200505656B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550605B2 (en) * 2004-08-05 2009-06-23 Sun Pharmaceutical Industries Ltd. Process for preparation of an anitdepressant compound
CZ297560B6 (cs) 2004-10-26 2007-02-07 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
TWI306858B (en) * 2004-12-23 2009-03-01 Teva Pharma Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
EP1776049A2 (en) * 2005-01-27 2007-04-25 Teva Pharmaceutical Industries Ltd. Duloxetine hcl polymorphs
WO2006096809A1 (en) 2005-03-08 2006-09-14 Teva Pharmaceutical Industries Ltd. Crystal forms of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine oxalate and the preparation thereof
TW200639162A (en) * 2005-03-14 2006-11-16 Teva Pharma Pure duloxetine hydrochloride
US8093408B2 (en) * 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
US8153824B2 (en) * 2005-06-22 2012-04-10 The Wockhardt Company Antidepressant oral liquid compositions
WO2007038253A2 (en) * 2005-09-22 2007-04-05 Teva Pharmaceutical Industries Ltd. Dnt-maleate and methods of preparation thereof
EP1863782A1 (en) * 2005-12-05 2007-12-12 Teva Pharmaceutical Industries Ltd. 2-(n-methyl-propanamine)-3-(2-naphtol) thiophene, an imputity of duloxetine hydrochloride
EP1971593A2 (en) * 2005-12-12 2008-09-24 Medichem, S.A. Improved synthesis and preparations of duloxetine salts
CZ299270B6 (cs) * 2006-01-04 2008-06-04 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
EP1976844A4 (en) * 2006-01-06 2010-11-03 Msn Lab Ltd IMPROVED METHOD FOR PURE DULOXETIN HYDROCHLORIDE
US7538232B2 (en) 2006-01-19 2009-05-26 Eli Lilly And Company Process for the asymmetric synthesis of duloxetine
CA2640212A1 (en) * 2006-02-13 2007-08-23 Teva Pharmaceutical Industries Ltd. A process for the preparation of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, a duloxetine intermediate
HU228458B1 (en) * 2006-03-13 2013-03-28 Egis Gyogyszergyar Nyrt Duloxetine salts for producing pharmaceutical compositions
SI1857451T1 (sl) 2006-05-05 2010-11-30 Fidia Farmaceutici Postopek priprave intermediata ki je uporaben zaasimetrično sintezo duloksetina
US20080027128A1 (en) * 2006-05-23 2008-01-31 Santiago Ini Duloxetine HCL polymorphs
EP2044049A2 (en) 2006-07-03 2009-04-08 Ranbaxy Laboratories Limited Process for the preparation of enantiomerically pure salts of n-methyl- 3 -( 1-naph-thaleneoxy)- 3 - (-2-thienyl) propanamine
CZ300116B6 (cs) * 2006-12-05 2009-02-11 Zentiva, A. S. Zpusob cištení hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
HU227730B1 (en) 2006-12-22 2012-01-30 Richter Gedeon Nyrt Process for the preparation of duloxetine and for their the intermediates
CN101657438A (zh) 2006-12-22 2010-02-24 斯索恩有限公司 制备度洛西汀和相关化合物的方法
US8269023B2 (en) 2007-03-05 2012-09-18 Lupin Ltd. Process for preparation of duloxetine hydrochloride
WO2009019719A2 (en) * 2007-08-09 2009-02-12 Ind-Swift Laboratories Limited Process for the preparation of 3-aryloxy-3-arylpropanamines
WO2009130708A2 (en) * 2008-04-22 2009-10-29 Shodhana Laboratories Limited Preparation of duloxetine and its salts
WO2010025287A2 (en) 2008-08-27 2010-03-04 Codexis, Inc. Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
EP2329013B1 (en) 2008-08-27 2015-10-28 Codexis, Inc. Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
WO2011033366A2 (en) 2009-09-16 2011-03-24 Jubilant Life Sciences Limited Process for the preparation of duloxetine hydrochloride and its precursors
CN103360365A (zh) * 2012-04-06 2013-10-23 李晓红 一种抗抑郁症药物原料药盐酸度洛西汀的制备新工艺
CN104230882B (zh) * 2014-08-29 2017-03-08 宁波美诺华药业股份有限公司 一种度洛西汀盐酸盐杂质的制备方法
CN104829587B (zh) * 2015-05-08 2017-07-21 上海万巷制药有限公司 盐酸度洛西汀的制备
CN107382958B (zh) * 2017-07-05 2021-11-09 浙江华海药业股份有限公司 一种度洛西汀中间体的结晶方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH578532A5 (https=) * 1971-08-03 1976-08-13 Cassella Farbwerke Mainkur Ag
PL233786A1 (https=) 1980-11-14 1982-05-24 Lilly Co Eli
US4777291A (en) * 1985-02-27 1988-10-11 Eli Lilly And Company Racemization process
JPS62286959A (ja) * 1986-06-05 1987-12-12 Seitetsu Kagaku Co Ltd 光学活性シアノカルニチン塩の製造方法
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
KR880007433A (ko) * 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
CA2042346A1 (en) * 1990-05-17 1991-11-18 Michael Alexander Staszak Chiral synthesis of 1-aryl-3-aminopropan-1-ols
JPH09176157A (ja) * 1992-12-09 1997-07-08 Takeda Chem Ind Ltd 光学活性アミノクマラン誘導体
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
US6458955B1 (en) 1994-12-16 2002-10-01 Uop Llc Process for preparation of pharmaceutically desired enantiomers
US6162949A (en) 1994-12-16 2000-12-19 Uop Llc Process for preparation of the pharmaceutically desired (S)-oxetine enantiomers
EP0792649A1 (en) * 1996-02-29 1997-09-03 Eli Lilly And Company Treatment of sleep disorders
HUP0101901A3 (en) * 1998-05-22 2002-06-28 Lilly Co Eli Pharmaceutical composition for combined therapeutic treatment of refractory depression and combined treating process
CA2350531A1 (en) * 1998-11-13 2000-05-25 Smriti Iyengar Method for treating pain
ATE309196T1 (de) * 1999-04-09 2005-11-15 Lilly Co Eli Verfahren zur herstellung von 3-aryloxy-3- arylpropylamine und deren zwischenprodukte
WO2001044166A1 (en) * 1999-12-17 2001-06-21 Ranbaxy Laboratories Limited Process for the preparation of fluoxetine hydrochloride
WO2003062219A1 (en) 2002-01-24 2003-07-31 Eli Lilly And Company Process for preparing an intermediate useful for the asymmetric synthesis of duloxetine

Also Published As

Publication number Publication date
RU2351594C2 (ru) 2009-04-10
EP1690861B1 (en) 2012-09-12
NZ569874A (en) 2009-11-27
DE60311599T2 (de) 2007-10-25
ES2279971T3 (es) 2007-09-01
AU2003292396B2 (en) 2010-05-20
CN1747947A (zh) 2006-03-15
AU2010200142A1 (en) 2010-02-04
PT1587801E (pt) 2007-04-30
NZ540881A (en) 2008-09-26
ATE353081T1 (de) 2007-02-15
EP1690861A2 (en) 2006-08-16
EP1587801A1 (en) 2005-10-26
IL169232A (en) 2010-02-17
WO2004056795A8 (en) 2005-08-11
CA2510750A1 (en) 2004-07-08
KR20050089839A (ko) 2005-09-08
EP1587801B1 (en) 2007-01-31
CN100579975C (zh) 2010-01-13
MXPA05006659A (es) 2006-02-22
ZA200505656B (en) 2006-04-26
HRP20050657A2 (en) 2005-10-31
JP2006514030A (ja) 2006-04-27
JP5259048B2 (ja) 2013-08-07
AU2010200142B2 (en) 2012-04-12
EP1690861A3 (en) 2006-09-06
RU2005122662A (ru) 2006-01-20
DE60311599D1 (de) 2007-03-22
TNSN05167A1 (en) 2007-05-14
MA27706A1 (fr) 2006-01-02
PL377380A1 (pl) 2006-02-06
US7645890B2 (en) 2010-01-12
AU2003292396A1 (en) 2004-07-14
BR0316902A (pt) 2005-10-25
US20060205956A1 (en) 2006-09-14
KR100926723B1 (ko) 2009-11-16
IS7915A (is) 2005-06-24
CN101125848B (zh) 2012-09-12
WO2004056795A1 (en) 2004-07-08
CN101125848A (zh) 2008-02-20

Similar Documents

Publication Publication Date Title
GB0229583D0 (en) A process for preparing duloxetine and intermediates for use therein
NZ598172A (en) Synthesis of boronic ester and acid compounds
SI1781683T1 (sl) Postopek za pripravo 17-vinil-triflatov kot intermediatov
WO2006004100A8 (ja) １，２－ジヒドロピリジン－２－オン化合物の製造方法
IL175024A0 (en) Method for producing 2-dihaloacyl-3-amino-acrylic acid esters and 3-dihalomethyl-pyrazole-4-carboxylic acid esters
PT1038875E (pt) Derivados de imidazopiridina e processo para os preparar
HUP0300856A2 (hu) Eljárás szubsztituált fenil-acetonitrilek elżállítására
BR0308345A (pt) Processo para derivados de ácido trans-4-amino-1-cicloexanocarboxìlico
IT1319196B1 (it) Sintesi dell'acido r(+)alfa-lipoico.
EP1238977A4 (en) METHOD FOR PRODUCING PYRIDINE METHANOL COMPOUNDS
EP1215206A4 (en) METHOD FOR THE PRODUCTION OF 4 (5) -AMINO-5 (4) -CARBOXAMIDOIMIDAZOLES AND THEIR INTERMEDIATE PRODUCTS
EA200000924A2 (ru) СПОСОБ ПОЛУЧЕНИЯ ПИРАЗОЛО[4,3-d]ПИРИМИДИН-7-ОН-3-ПИРИДИЛСУЛЬФОНИЛЬНЫХ СОЕДИНЕНИЙ И ИХ ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ
NZ530111A (en) Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof
WO2003066653A3 (en) Process for the production of fluticasone propionate, in particular of polymorphic form 1
MEP1708A (xx) Postupak proizvodnje thip-a
EP1211239A4 (en) PROCESSES FOR THE PREPARATION OF 2,3-DIHYDROAZEPINE COMPOUNDS
BR0317781A (pt) Processo para produção de derivado de benzilamina
WO2003042183A1 (en) Process for production of pyrazole compounds
HU0204401D0 (en) Process for producing 2,6-dichlorophenol derivatives
IL146759A0 (en) Process for production of substituted alkylamine derivative
EP1219610A4 (en) PROCESS FOR THE PREPARATION OF OXAZOLE DERIVATIVES
EP0658542A4 (en) METHOD FOR PRODUCING ALPHA-HYDROXIMINOPHENYLACETONITRILE.
WO2005046854A3 (en) A process for the preparation of diphenylmethylsulfinyl derivatives
TW200505929A (en) Benzoxepino-11-piperidylidene compound and method of producing the same

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)